文献速递儿童感染儿童呼吸

奥司他韦对住院流感儿童的有效性:2014-2023年队列研究

Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023.
PubMed 文献 · JAMA Pediatr · 2026-01-01

该队列研究基于美国13州流感住院监测网络2014-2023年数据,纳入实验室确诊流感住院儿童。调整模型显示,奥司他韦治疗与ICU入住风险降低31%及住院时间缩短相关,支持当前国家推荐对住院疑似或确诊流感儿童尽早使用奥司他韦。

要点

  • 住院流感儿童接受奥司他韦与ICU入住风险降低31%相关(aHR 0.69)。
  • 奥司他韦治疗与住院时间缩短相关(出院风险aHR 1.13)。
  • 结果支持对住院疑似或确诊流感儿童尽早使用奥司他韦。

核心结论

  • 在住院流感儿童中,奥司他韦治疗与ICU入住风险降低31%及住院时间缩短显著相关,支持当前国家推荐尽早治疗。

研究设计与样本

  • 基于美国13州人群监测网络(FluSurv-NET)的队列研究,纳入2014-2015至2022-2023季(排除2020-2021季)实验室确诊流感住院且已知呼吸道症状起始日期的18岁以下儿童。
  • ICU分析纳入6044例,其中4240例(70.2%)接受奥司他韦;住院时间分析纳入7103例,其中5746例(80.9%)接受奥司他韦。
  • 奥司他韦作为时间依赖性暴露,采用调整Cox比例风险模型分析。

主要发现

  • ICU分析中位年龄3岁(IQR 1-7),男性3382例(56%),女性3721例(44%),2937例(49%)有至少一种基础疾病,最常见为哮喘1547例(26%)。
  • 调整模型显示,与未治疗儿童相比,奥司他韦治疗降低ICU入住风险(aHR 0.69;95% CI 0.60-0.80)。
  • 奥司他韦治疗缩短住院时间(以出院风险分析,aHR 1.13;95% CI 1.06-1.21)。

关键数值与推荐

  • 奥司他韦治疗与ICU入住风险降低31%相关(aHR 0.69;95% CI 0.60-0.80)。
  • 奥司他韦治疗与住院时间缩短相关(出院风险aHR 1.13;95% CI 1.06-1.21)。

临床怎么用

  • 对住院的疑似或实验室确诊流感儿童,应尽早开始奥司他韦治疗,以降低ICU入住风险和缩短住院时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: National organizations recommend antiviral treatment for hospitalized children with influenza; however, use in this setting has recently declined. Studies of oseltamivir effectiveness in children are limited by misclassification bias, unknown symptom onset date, and incomplete capture of antiviral use prior to admission. OBJECTIVE: To assess the association between oseltamivir receipt and intensive care unit (ICU) admission and hospital length of stay (LOS) among pediatric influenza-associated hospitalizations. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data that were obtained from the Influenza Hospitalization Surveillance Network (FluSurv-NET), which conducts US population-based surveillance for laboratory-confirmed influenza hospitalizations for all ages across 13 states. The study data include seasons 2014 to 2015 through 2022 to 2023, excluding 2020 to 2021. Participants included children aged younger than 18 years who were hospitalized with laboratory-confirmed influenza and for whom a respiratory symptom onset date was available. These data were analyzed from October 2024 through May 2026. EXPOSURES: Oseltamivir receipt as a time-dependent exposure. MAIN OUTCOME(S) AND MEASURE(S): The primary outcome was time from symptom onset to ICU admission. Secondary outcome was time from admission to discharge (LOS). Adjusted Cox proportional hazard models (aHR) with oseltamivir receipt as a time-dependent exposure were used. RESULTS: After exclusions, 6044 influenza cases were included in the primary ICU analysis, of whom 4240 (70.2%) received oseltamivir, and 7103 cases were included in the secondary LOS analysis, of whom 5746 (80.9%) received oseltamivir. In the ICU analysis, the median (IQR) age was 3 (1-7) years, 3382 (56%) were male and 3721 (44%) were female, and 2937 (49%) had 1 or more medical comorbidity-the most common of which was asthma in 1547 children (26%). In adjusted models, compared with untreated children, oseltamivir treatment reduced the hazard of ICU admission (aHR, 0.69; 95% CI, 0.60-0.80) and shortened LOS (analyzed as hazard of hospital discharge; aHR, 1.13; 95% CI, 1.06-1.21). CONCLUSIONS AND RELEVANCE: In this cohort of children hospitalized with influenza, oseltamivir treatment was significantly associated with a reduced risk of ICU admission by 31% and decreased hospital LOS. These findings demonstrate the benefits of oseltamivir receipt and support current national recommendations for oseltamivir treatment as soon as possible in children hospitalized with suspected or laboratory-confirmed influenza.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Rytlewski K, Dunn A, O'Halloran A, et al. Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023. JAMA Pediatr. 2026. PMID: 42573991. doi:10.1001/jamapediatrics.2026.3376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。